JP6723230B2 - 神経障害性疼痛を治療するためのｃｓｆ１−ｄａｐ１２経路のメンバー遺伝子の標的破壊 - Google Patents

神経障害性疼痛を治療するためのｃｓｆ１−ｄａｐ１２経路のメンバー遺伝子の標的破壊 Download PDF

Info

Publication number
JP6723230B2
JP6723230B2 JP2017518840A JP2017518840A JP6723230B2 JP 6723230 B2 JP6723230 B2 JP 6723230B2 JP 2017518840 A JP2017518840 A JP 2017518840A JP 2017518840 A JP2017518840 A JP 2017518840A JP 6723230 B2 JP6723230 B2 JP 6723230B2
Authority
JP
Japan
Prior art keywords
csf1
promoter
vector
hcsf1
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017518840A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532035A (ja
JP2017532035A5 (https=
Inventor
アラン バスバウム
アラン バスバウム
ジュリア クーン
ジュリア クーン
チョンフイ グアン
チョンフイ グアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Los Angeles UCLA
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2017532035A publication Critical patent/JP2017532035A/ja
Publication of JP2017532035A5 publication Critical patent/JP2017532035A5/ja
Application granted granted Critical
Publication of JP6723230B2 publication Critical patent/JP6723230B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017518840A 2014-10-09 2015-10-08 神経障害性疼痛を治療するためのｃｓｆ１−ｄａｐ１２経路のメンバー遺伝子の標的破壊 Expired - Fee Related JP6723230B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062047P 2014-10-09 2014-10-09
US62/062,047 2014-10-09
PCT/US2015/054704 WO2016057800A1 (en) 2014-10-09 2015-10-08 Targeted disruption of a csf1-dap12 pathway member gene for the treatment of neuropathic pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020107553A Division JP2020191877A (ja) 2014-10-09 2020-06-23 神経障害性疼痛を治療するためのｃｓｆ１−ｄａｐ１２経路のメンバー遺伝子の標的破壊

Publications (3)

Publication Number Publication Date
JP2017532035A JP2017532035A (ja) 2017-11-02
JP2017532035A5 JP2017532035A5 (https=) 2018-11-15
JP6723230B2 true JP6723230B2 (ja) 2020-07-15

Family

ID=55653779

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017518840A Expired - Fee Related JP6723230B2 (ja) 2014-10-09 2015-10-08 神経障害性疼痛を治療するためのｃｓｆ１−ｄａｐ１２経路のメンバー遺伝子の標的破壊
JP2020107553A Pending JP2020191877A (ja) 2014-10-09 2020-06-23 神経障害性疼痛を治療するためのｃｓｆ１−ｄａｐ１２経路のメンバー遺伝子の標的破壊

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020107553A Pending JP2020191877A (ja) 2014-10-09 2020-06-23 神経障害性疼痛を治療するためのｃｓｆ１−ｄａｐ１２経路のメンバー遺伝子の標的破壊

Country Status (5)

Country Link
US (2) US20170354745A1 (https=)
EP (1) EP3204050A4 (https=)
JP (2) JP6723230B2 (https=)
CA (1) CA2963940A1 (https=)
WO (1) WO2016057800A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
JP7305534B2 (ja) 2016-07-06 2023-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛関連障害を処置するための物質及び方法
CN109843914B (zh) * 2016-07-06 2024-03-15 沃泰克斯药物股份有限公司 用于治疗疼痛相关病症的材料和方法
SG11202002481RA (en) 2017-09-19 2020-04-29 Tropic Biosciences Uk Ltd Modifying the specificity of non-coding rna molecules for silencing gene expression in eukaryotic cells
CN107557394A (zh) * 2017-09-29 2018-01-09 南京鼓楼医院 降低CRISPR/Cas9介导的胚胎基因编辑脱靶率的方法
GB201903519D0 (en) * 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest
AU2020384935A1 (en) * 2019-11-15 2022-06-09 Nogra Pharma Limited IL-34 antisense agents and methods of using same
GB201918879D0 (en) * 2019-12-19 2020-02-05 Ucl Business Ltd Treatment of chronic pain
CA3197730A1 (en) 2020-10-15 2022-04-21 F. Hoffman-La Roche Ag Nucleic acid constructs for va rna transcription
EP4229204A1 (en) 2020-10-15 2023-08-23 F. Hoffmann-La Roche AG Nucleic acid constructs for simultaneous gene activation
AU2022276078A1 (en) 2021-05-17 2024-01-04 Nogra Pharma Limited Il-34 antisense agents and methods of using same
JP2024534945A (ja) 2021-09-10 2024-09-26 アジレント・テクノロジーズ・インク 化学修飾を有するプライム編集のためのガイドｒｎａ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009019528A1 (en) * 2007-08-03 2009-02-12 Cellectis Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
US9173928B2 (en) * 2009-03-26 2015-11-03 Yoh Matsumoto DNA vaccine for Alzheimer's disease
EP2563921B1 (en) * 2010-04-30 2016-11-23 Cellectis Method for modulating double-strand break-induced homologous recombination
DK2734547T3 (en) * 2011-07-18 2017-04-03 Univ Melbourne USE OF C-FMS ANTIBODIES
EP3031921B1 (en) * 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

Also Published As

Publication number Publication date
US20200030459A1 (en) 2020-01-30
WO2016057800A1 (en) 2016-04-14
JP2017532035A (ja) 2017-11-02
JP2020191877A (ja) 2020-12-03
EP3204050A1 (en) 2017-08-16
US20170354745A1 (en) 2017-12-14
CA2963940A1 (en) 2016-04-14
EP3204050A4 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
JP6723230B2 (ja) 神経障害性疼痛を治療するためのｃｓｆ１−ｄａｐ１２経路のメンバー遺伝子の標的破壊
KR102259006B1 (ko) 인위적으로 조작된 신생혈관형성 조절 시스템
US20230250407A1 (en) Silencing of dux4 by recombinant gene editing complexes
CN114230675B (zh) Rna指导的基因编辑和基因调节
JP2023145597A (ja) Ｒｎａを編集するための組成物および方法
KR102670361B1 (ko) 유전자 발현 조절을 위한 인위적인 게놈 조작
JP2021521855A (ja) ヘモグロビン関連変異の編集のための相同組換え修復用鋳型の設計およびその送達
US20210260168A1 (en) Compositions and methods of fas inhibition
WO2019010091A1 (en) METHODS AND COMPOSITIONS FOR FACILITATING HOMOLOGOUS RECOMBINATION
CA3115902A1 (en) Selection by means of artificial transactivators
KR20200011899A (ko) 인위적인 유전자 조작을 통한 자가면역질환 치료
WO2023135318A1 (en) Method for expression of a transgene of interest from neural precursor cells
JP2020528735A (ja) 反復伸長変異のためのゲノム編集システム
US20230220361A1 (en) Crispr-cas9 mediated disruption of alcam gene inhibits adhesion and trans-endothelial migration of myeloid cells
WO2020006708A1 (en) Compositions and methods for enhancement of homology-directed repair mediated precise gene editing by programming dna repair with a single rna-guided endonuclease
Lopes et al. Gene Editing for ATXN3 Inactivation in Machado-Joseph disease: CRISPR-Cas9 as a Therapeutic Alternative to TALEN-Induced Toxicity
Del Fiore Discovering regulators of HNF1B activity by CRISPR interference
Pagliari Optimization of AAV9 gene therapy for Spinal Muscular Atrophy with Respiratory Distress type 1 using in vivo disease models
Almeida Genome editing of Mesenchymal stem/stromal cells (MSCs) by CRISPR/Cas9 technology for azurin-based anticancer therapies
LLADO SANTAEULARIA THERAPEUTIC GENOME EDITING IN RETINA AND LIVER
CA3249049A1 (en) TELOMERAS REVERSE TRANSCRIPTASE THERAPY FOR RENAL FIBROSIS AND ASSOCIATED NON-HUMAN ANIMALS
Cring Genetic therapeutic strategies for Bardet-Biedl Syndrome
HK40126455A (zh) Rna指导的基因编辑和基因调节
HK40108790A (zh) 具有氧化应激抗性的间充质干细胞、其制备方法及用途
HK40035616B (zh) 用於基因表逹调节的人工基因组操纵

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200525

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200623

R150 Certificate of patent or registration of utility model

Ref document number: 6723230

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees